SCHEMBL23933112

SCHEMBL23933112

COC(=O)C12CC(C=NNS(=O)(=O)c3ccc(C)cc3)(C1)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.47
MEN1 O00255 10/20 0.47
ALDH1A1 P00352 7/20 0.45
POLB P06746 3/20 0.45
MAPT P10636 5/20 0.43
LMNA P02545 2/20 0.43
F2 P00734 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43
RECQL P46063 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALOX12 P18054 2/20 0.42
HTT P42858 2/20 0.42
CYP2C9 P11712 3/20 0.41
CYP2C19 P33261 3/20 0.41
CYP3A4 P08684 1/20 0.41
PKM P14618 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23933111 1.00 KMT2A (0.47) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL31736490 0.89 MEN1 (0.49) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL30184806 0.81 KMT2A (0.49) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL29768849 0.81 ALDH1A1 (0.46) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL23933134 0.81 F2 (0.47) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL23933135 0.81 F2 (0.47) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL29843445 0.74 KMT2A (0.49) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL26388343 0.71 ALDH1A1 (0.45) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL23172046 0.70 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL27131285 0.69 MAPT (0.50) KMT2AMEN1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4271387-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF Immunext, Inc. (US) 2023-11-08 EP disclosed
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 US disclosed
EP-4136118-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF Immunext, Inc. (US) 2023-02-22 EP disclosed
WO-2022150637-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF IMMUNEXT, INC. (US) 2022-07-14 WO disclosed
WO-2021216913-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT, INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A KMT2A 1155/4885MEN1 2750/4885ALDH1A1 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.